Health
J&J says late-stage COVID-19 vaccine trial fully enrolled – Reuters
Johnson & Johnson said on Thursday it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate.
By Reuters Staff
Dec 17 (Reuters) – Johnson & Johnson said on Thursday it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate.
The study, named Ensemble, has enrolled about 45,000 participants and is being conducted by its unit Janssen, J&J said here in a statement, adding that it expects interim data from the trial by the end of January 2021.
J&J also said it plans to submit an emergency use authorization application to the U.S. Food and…
-
General22 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General21 hours agoJaguar Land Rover in UK pauses shipments to US
-
General19 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General17 hours agoAustralian share market set to dive as threat of US recession grows